About Modunai Therapeutics

Pioneering Stress-Adaptation Biology to Overcome Therapy Resistance.

Modunai Therapeutics is advancing a new class of AI-engineered antibody medicines that eliminate residual and resistant disease in cancer and autoimmunity. Leveraging the emerging field of stress-adaptation biology, we design bispecific and pH-selective antibody-drug conjugate (ADC) therapeutics that precisely target key biological drivers of therapy escape.

🌍 Mission & Vision

Advancing precision biologics that turn therapy resistance into vulnerability and relapse into remission—delivering durable cures for cancer and immune-mediated diseases.

👩‍🔬 Founding Team

Founded by entrepreneurs and scientists with deep expertise in bispecific and ADC discovery, immunology, and translational science, Modunai’s team has advanced programs from concept to clinic, united by a mission to transform stress-adaptation biology into novel therapeutics for unmet needs.

Our Science

Harnessing Stress-Adaptation Biology to Overcome Therapy Resistance

Despite transformative advances in oncology, therapy resistance remains the ultimate barrier to cure. Standard treatments—including chemotherapy, radiation, and immunotherapy—induce stress that enables tumors to adapt, survive, and relapse. No existing strategy fully addresses this core vulnerability.

Modunai Therapeutics pioneers a new precision approach—turning stress adaptation into a therapeutic opportunity. Our pipeline is built on two synergistic strategies:

Extrinsic Stress Modulation via Tumor-Targeted Bispecific Antibodies

We engineer AI-guided bispecific biologics that target stress mediators in the tumor microenvironment, dismantling immune-suppressive niches and sensitizing tumors to checkpoint inhibitors and chemoradiation.

Intrinsic Stress Targeting with pH-Selective Antibody–Drug Conjugates (ADCs)

We develop pH-selective ADCs that recognize stress pathways in resistant tumors. Integrated with theranostics, these ADCs detect and eliminate residual resistant clones, aiming for curative precision.

Together, these platforms harness therapy-induced vulnerabilities to eliminate the very resistance therapies create. Beyond oncology, our AI-driven stress biology platform extends to autoimmune and inflammatory diseases.

Together, Modunai's complementary platforms harness therapy-induced vulnerabilities to overcome resistance. Beyond oncology, our AI-driven stress biology platform extends to autoimmune and inflammatory diseases—transforming therapy resistance into durable remission.

Targeting Stress Adaptation in Cancer Resistance

Tumor Relapse

Pipeline

Advancing AI-engineered bispecific antibodies and ADCs that modulate tumor stress pathways to overcome therapy resistance.

Opportunities

Modunai Therapeutics is advancing first-in-class biologics that transform therapy resistance into lasting remission. Our AI-enabled discovery platform combines antibody engineering with stress-adaptation biology to create bispecific and ADC therapeutics with strong translational potential. We are actively building strategic partnerships and investor collaborations to advance our lead programs toward preclinical proof-of-concept.